Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q2 2026 | 2026-08-17 | $0.9400 |
| Q1 2026 | 2026-05-19 | $0.9400 |
| Q1 2026 | 2026-02-19 | $0.9400 |
| Q3 2025 | 2025-11-19 | $0.8800 |
| Q2 2025 | 2025-08-17 | $0.8800 |
| Q2 2025 | 2025-05-19 | $0.8800 |
| Q2 2025 | 2025-02-19 | $0.8800 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.… The company's products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron's core business strategy is to maintain a strong foundation in scientific research and drug development using its proprietary technologies, and to build on that foundation with its clinical development, manufacturing, and commercial capabilities. The company has 15 approved or authorized medicines to date, spanning ophthalmology, immunology and inflammation, cancer, hematology, cardiovascular diseases, and rare diseases. Key marketed products include EYLEA HD and EYLEA (aflibercept) for retinal diseases, Dupixent (dupilumab) for allergic and inflammatory conditions, Libtayo (cemiplimab) for cancer, Praluent (alirocumab) for cardiovascular risk reduction, and others. The company operates approximately 50 clinical candidates across multiple therapeutic areas and invests significantly in R&D ($5.9 billion in 2025), representing approximately 41% of total revenues. Regeneron utilizes proprietary technologies including VelociSuite platforms and maintains the Regeneron Genetics Center for data-driven drug discovery and development.
- Name
- Regeneron Pharmaceuticals, Inc.
- Industry
- Drug Manufacturers - General
- CEO
- Leonard S. Schleifer · Board co-Chair, President and Chief Executive Officer
- Employees
- 15,000 as of 2025-12-31
- IPO Date
- 2017-01-31
- Phone
- (914) 847-7000
- Address
- 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
- Website
- http://www.regeneron.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Joseph J. LaRosa | Executive Vice President, General Counsel and Secretary | — |
| Robert E. Landry | Chief Financial Officer | — |
| George D. Yancopoulos | Board co-Chair, President and Chief Scientific Officer | — |
| Leonard S. Schleifer | Board co-Chair, President and Chief Executive Officer | — |
Latest News
- 2026-04-24
- 2026-04-24
- 2026-04-24
- 2026-04-24
- 2026-04-23
- 2026-04-23
- 2026-04-23
- 2026-04-23